| 2.15 0.1 (4.88%) | 09-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.65 | 1-year : | 3.09 |
| Resists | First : | 2.26 | Second : | 2.65 |
| Pivot price | 1.99 |
|||
| Supports | First : | 1.83 | Second : | 1.57 |
| MAs | MA(5) : | 2.07 |
MA(20) : | 1.91 |
| MA(100) : | 3.13  |
MA(250) : | 13.21 |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 73.6 |
D(3) : | 74.7 |
| RSI | RSI(14): 57 |
|||
| 52-week | High : | 35.25 | Low : | 0.82 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ JAGX ] has closed below upper band by 4.8%. Bollinger Bands are 86.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 83 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.15 - 2.16 | 2.16 - 2.17 |
| Low: | 2.01 - 2.02 | 2.02 - 2.03 |
| Close: | 2.13 - 2.15 | 2.15 - 2.17 |
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic, and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer for multiple possible follow-on indications, including cancer therapy-related diarrhea; orphan-drug indications for symptomatic relief of diarrhea in infants and children with congenital diarrheal disorders and for adult and pediatric patients for short bowel syndrome with intestinal failure with; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops lechlemer, a second-generation anti-secretory agent for cholera; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. Jaguar Health, Inc. was founded in 2013 and is headquartered in San Francisco, California.
Thu, 25 Sep 2025
Jaguar Health (JAGX) Secures FDA Grant for Canalevia Study - GuruFocus
Tue, 23 Sep 2025
Biotech Leader Jaguar Health Sets Dual Conference Appearances: Key Updates Coming at September Events - Stock Titan
Sun, 21 Sep 2025
Jaguar Health Completes Private Placement Deal - MSN
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 2 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 34.7 (%) |
| Held by Institutions | 0.6 (%) |
| Shares Short | 66 (K) |
| Shares Short P.Month | 44 (K) |
| EPS | 37.52 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.59 |
| Profit Margin | 0 % |
| Operating Margin | -268.8 % |
| Return on Assets (ttm) | -37.5 % |
| Return on Equity (ttm) | -319.3 % |
| Qtrly Rev. Growth | 9.5 % |
| Gross Profit (p.s.) | 4.45 |
| Sales Per Share | 5.44 |
| EBITDA (p.s.) | -14.26 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -28 (M) |
| Levered Free Cash Flow | -16 (M) |
| PE Ratio | 0.05 |
| PEG Ratio | 0 |
| Price to Book value | 0.59 |
| Price to Sales | 0.39 |
| Price to Cash Flow | -0.17 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|